JP4542266B2 - 浮腫の治療に使用されるｔｎｆ由来のペプチド - Google Patents
浮腫の治療に使用されるｔｎｆ由来のペプチド Download PDFInfo
- Publication number
- JP4542266B2 JP4542266B2 JP2000564651A JP2000564651A JP4542266B2 JP 4542266 B2 JP4542266 B2 JP 4542266B2 JP 2000564651 A JP2000564651 A JP 2000564651A JP 2000564651 A JP2000564651 A JP 2000564651A JP 4542266 B2 JP4542266 B2 JP 4542266B2
- Authority
- JP
- Japan
- Prior art keywords
- tnf
- peptide
- edema
- peptides
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 72
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 27
- 206010030113 Oedema Diseases 0.000 title claims abstract description 26
- 206010037423 Pulmonary oedema Diseases 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000005333 pulmonary edema Diseases 0.000 claims description 8
- 235000018417 cysteine Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 3
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 110
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 110
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract description 6
- 102000057041 human TNF Human genes 0.000 abstract description 6
- 230000001939 inductive effect Effects 0.000 abstract description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 29
- 230000000694 effects Effects 0.000 description 29
- 210000004072 lung Anatomy 0.000 description 28
- 239000012528 membrane Substances 0.000 description 25
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 19
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 19
- 101100046526 Mus musculus Tnf gene Proteins 0.000 description 17
- 150000001413 amino acids Chemical group 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 230000002378 acidificating effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 108010021152 pepBs1-Ac peptide Proteins 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000000503 lectinlike effect Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- -1 3-sulfopropyl Chemical group 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000011533 pre-incubation Methods 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 230000000171 quenching effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 5
- 229960002576 amiloride Drugs 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 210000003038 endothelium Anatomy 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 206010034674 peritonitis Diseases 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 231100000057 systemic toxicity Toxicity 0.000 description 4
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 102000008072 Lymphokines Human genes 0.000 description 3
- 108010074338 Lymphokines Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000223105 Trypanosoma brucei Species 0.000 description 3
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 208000000230 African Trypanosomiasis Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010052164 Sodium Channels Proteins 0.000 description 2
- 102000018674 Sodium Channels Human genes 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 208000029080 human African trypanosomiasis Diseases 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000002612 sleeping sickness Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 108010073254 Colicins Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000007605 Cytochromes b5 Human genes 0.000 description 1
- 108010007167 Cytochromes b5 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010051604 Lung transplant rejection Diseases 0.000 description 1
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 1
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101100425758 Mus musculus Tnfrsf1b gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- CDOJPCSDOXYJJF-CBTAGEKQSA-N N,N'-diacetylchitobiose Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CDOJPCSDOXYJJF-CBTAGEKQSA-N 0.000 description 1
- 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000004231 Riboflavin-5-Sodium Phosphate Substances 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101150009046 Tnfrsf1a gene Proteins 0.000 description 1
- 206010057179 Toxoplasma infections Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 235000010730 Ulex europaeus Nutrition 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 208000012871 acute dyspnea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000005219 defense response to fungus Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008846 dynamic interplay Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-O hydron;quinoline Chemical compound [NH+]1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-O 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010220 ion permeability Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 210000005063 microvascular endothelium Anatomy 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Inorganic materials [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000007047 pulmonary toxicity Effects 0.000 description 1
- 230000008695 pulmonary vasoconstriction Effects 0.000 description 1
- 230000008704 pulmonary vasodilation Effects 0.000 description 1
- 108010003189 recombinant human tumor necrosis factor-binding protein-1 Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108010072415 tumor necrosis factor precursor Proteins 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98870180 | 1998-08-14 | ||
| EP98870180.1 | 1998-08-14 | ||
| EP98870198.3 | 1998-09-18 | ||
| EP98870198 | 1998-09-18 | ||
| EP98870222.1 | 1998-10-21 | ||
| EP98870222 | 1998-10-21 | ||
| PCT/EP1999/005806 WO2000009149A1 (en) | 1998-08-14 | 1999-08-10 | Tnf-derived peptides for use in treating oedema |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002522508A JP2002522508A (ja) | 2002-07-23 |
| JP2002522508A5 JP2002522508A5 (enExample) | 2006-09-21 |
| JP4542266B2 true JP4542266B2 (ja) | 2010-09-08 |
Family
ID=27239778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000564651A Expired - Lifetime JP4542266B2 (ja) | 1998-08-14 | 1999-08-10 | 浮腫の治療に使用されるｔｎｆ由来のペプチド |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20030105021A1 (enExample) |
| EP (3) | EP1247531B1 (enExample) |
| JP (1) | JP4542266B2 (enExample) |
| CN (1) | CN1181886C (enExample) |
| AT (2) | ATE395072T1 (enExample) |
| AU (1) | AU764992B2 (enExample) |
| BR (1) | BR9912899A (enExample) |
| CA (1) | CA2334941C (enExample) |
| CZ (1) | CZ302862B6 (enExample) |
| DE (2) | DE69938743D1 (enExample) |
| DK (1) | DK1264599T3 (enExample) |
| ES (1) | ES2296872T3 (enExample) |
| HU (1) | HU227661B1 (enExample) |
| IL (2) | IL141064A0 (enExample) |
| NZ (1) | NZ509604A (enExample) |
| PL (1) | PL203706B1 (enExample) |
| PT (1) | PT1264599E (enExample) |
| TR (1) | TR200100338T2 (enExample) |
| WO (1) | WO2000009149A1 (enExample) |
| ZA (1) | ZA200100656B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ509604A (en) | 1998-08-14 | 2003-05-30 | Innogenetics N | TNF-derived peptides for use in treating oedema |
| EP1781323B1 (en) | 2004-08-06 | 2010-02-17 | Nycomed GmbH | Composition comprising a pulmonary surfactant and a tnf-derived peptide |
| EP2009023A1 (en) * | 2007-06-04 | 2008-12-31 | Rentschler Beteiligungs GmbH | Novel peptides and their use for the treatment of edema |
| AT506150B1 (de) | 2007-12-12 | 2010-01-15 | Apeptico Forschung Und Entwick | Zyklisches und cystein-freies peptid |
| AT506151B1 (de) | 2007-12-12 | 2010-01-15 | Apeptico Forschung Und Entwick | Fusionsprotein |
| AT507953B1 (de) * | 2009-03-05 | 2011-02-15 | Apeptico Forschung & Entwicklung Gmbh | Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität |
| AT509267A1 (de) * | 2010-01-14 | 2011-07-15 | Apeptico Forschung & Entwicklung Gmbh | Organische verbindungen zur regulierung von vektoriellen ionenkanälen |
| DK2397151T3 (en) | 2010-06-21 | 2015-05-18 | Apeptico Forschung & Entwicklung Gmbh | The treatment of the vascular complications of diabetes |
| AT510585B1 (de) * | 2010-11-18 | 2012-05-15 | Apeptico Forschung & Entwicklung Gmbh | Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase |
| US11161881B2 (en) * | 2010-11-18 | 2021-11-02 | Apeptico Forschung Und Entwicklung Gmbh | Composition comprising a peptide and an inhibitor of viral neuraminidase |
| EP2679239A1 (de) * | 2012-06-28 | 2014-01-01 | Apeptico Forschung und Entwicklung GmbH | Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit |
| US12004506B2 (en) | 2013-04-23 | 2024-06-11 | Apeptico Forschung Und Entwicklung Gmbh | Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment |
| JP6335279B2 (ja) * | 2013-04-23 | 2018-05-30 | アペプティコ フオルシユング ウント アントウィクラング ゲーエムベーハー | 式ｘ１−ｇｑｒｅｔｐｅｇａｅａｋｐｗｙ−ｘ２の環状ペプチドを含んでなる医薬組成物および体外肺処置のための使用 |
| JP6397984B2 (ja) | 2014-03-18 | 2018-09-26 | アペプティコ・フォルシュング・ウント・エントヴィックルング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＡｐｅｐｔｉｃｏ Ｆｏｒｓｃｈｕｎｇ Ｕｎｄ Ｅｎｔｗｉｃｋｌｕｎｇ Ｇｍｂｈ | 乾燥粉末ペプチド医薬 |
| CN110613838A (zh) * | 2018-06-19 | 2019-12-27 | 姜石松 | 增强细胞通透性的多肽及其应用 |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| EP4051307B1 (en) | 2020-05-08 | 2023-02-01 | APEPTICO Forschung und Entwicklung GmbH | Peptide for prevention or treatment of covid-19 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE384179C (de) * | 1921-04-07 | 1923-10-27 | Ludwig Weil Dr | Laufrad fuer Kreiselpumpen und -geblaese |
| DE3841759A1 (de) | 1988-12-12 | 1990-06-13 | Basf Ag | Neue tnf-peptide |
| CA2155103A1 (en) * | 1993-02-03 | 1994-08-18 | Rudolph Lucas | Tnf-alpha muteins and a process for preparing them |
| NZ509604A (en) | 1998-08-14 | 2003-05-30 | Innogenetics N | TNF-derived peptides for use in treating oedema |
-
1999
- 1999-08-10 NZ NZ509604A patent/NZ509604A/en not_active IP Right Cessation
- 1999-08-10 EP EP02077274A patent/EP1247531B1/en not_active Expired - Lifetime
- 1999-08-10 IL IL14106499A patent/IL141064A0/xx unknown
- 1999-08-10 DK DK02077256T patent/DK1264599T3/da active
- 1999-08-10 EP EP02077256A patent/EP1264599B1/en not_active Expired - Lifetime
- 1999-08-10 DE DE69938743T patent/DE69938743D1/de not_active Expired - Lifetime
- 1999-08-10 CA CA2334941A patent/CA2334941C/en not_active Expired - Lifetime
- 1999-08-10 CN CNB998096555A patent/CN1181886C/zh not_active Expired - Lifetime
- 1999-08-10 AU AU56209/99A patent/AU764992B2/en not_active Ceased
- 1999-08-10 AT AT02077274T patent/ATE395072T1/de active
- 1999-08-10 JP JP2000564651A patent/JP4542266B2/ja not_active Expired - Lifetime
- 1999-08-10 BR BR9912899-3A patent/BR9912899A/pt active Search and Examination
- 1999-08-10 AT AT02077256T patent/ATE374039T1/de active
- 1999-08-10 EP EP99942835A patent/EP1105152A1/en not_active Withdrawn
- 1999-08-10 CZ CZ20010538A patent/CZ302862B6/cs not_active IP Right Cessation
- 1999-08-10 PT PT02077256T patent/PT1264599E/pt unknown
- 1999-08-10 WO PCT/EP1999/005806 patent/WO2000009149A1/en not_active Ceased
- 1999-08-10 HU HU0103117A patent/HU227661B1/hu not_active IP Right Cessation
- 1999-08-10 TR TR2001/00338T patent/TR200100338T2/xx unknown
- 1999-08-10 DE DE69937206T patent/DE69937206T2/de not_active Expired - Lifetime
- 1999-08-10 ES ES02077256T patent/ES2296872T3/es not_active Expired - Lifetime
- 1999-08-10 PL PL345997A patent/PL203706B1/pl unknown
-
2001
- 2001-01-23 ZA ZA2001/00656A patent/ZA200100656B/en unknown
- 2001-01-24 IL IL141064A patent/IL141064A/en not_active IP Right Cessation
- 2001-02-09 US US09/779,703 patent/US20030105021A1/en not_active Abandoned
-
2002
- 2002-06-06 US US10/162,553 patent/US7258861B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4542266B2 (ja) | 浮腫の治療に使用されるｔｎｆ由来のペプチド | |
| ES2363162T3 (es) | Composicones y procedimientos para el tratamiento de trastornos fibróticos. | |
| HU216318B (hu) | Eljárás a vérlemezkék aggregálódását gátló szerek, és az előállításukhoz alkalmas DNS-szekvenciák, vektorok és gazdasejtek előállítására | |
| EP3122783A1 (en) | Novel recombinant bi-functional fusion proteins, preparation and use thereof | |
| JP4173633B2 (ja) | 長いペントラキシンｐｔｘ３を含む医薬組成物 | |
| JP2004203890A (ja) | マクロファージ炎症蛋白変種 | |
| AU2015305299B2 (en) | Disintegrin variants and pharmaceutical uses thereof | |
| AU7520996A (en) | Method of mobilizing hematopoietic stem cells | |
| US11351227B2 (en) | Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof | |
| WO1999055361A1 (en) | Neovascularization inhibitors | |
| WO1996011700A1 (en) | Reduction of mammalian neoplasms with phospholipase a2 activatiing substances | |
| HK1051802A (en) | Tnf-derived peptides for use in treating oedema | |
| CN107083366A (zh) | 表达水蛭素的过继免疫细胞及其制备方法和用途 | |
| HK1051805B (en) | Tnf-derived peptides for use in treating oedema | |
| WO2012013110A1 (zh) | 具有抑制血管生成活性的多肽 | |
| CN101730710A (zh) | Vegf-d突变体及其用途 | |
| MXPA01001527A (en) | Tnf-derived peptides for use in treating oedema | |
| JPH083065A (ja) | 肝臓障害に対する治療剤 | |
| KR20010032511A (ko) | 조혈 간세포를 이동시키는 방법 | |
| WO2012081711A1 (ja) | 細胞遊走調節剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060802 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060802 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070829 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070829 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090825 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091125 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100421 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100513 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100601 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100625 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4542266 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130702 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |